Logo of Cyclopharm (ASX:CYC)Latest Cyclopharm (ASX:CYC) News

Page 1
Page 1 of 4

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Cyclopharm’s US Technegas rollout gathers pace as consumables drive record quarter

Cyclopharm has reported record third-quarter US Technegas revenue of A$1.62 million, with 76% generated by recurring consumable orders. Its installed base and hospital pipeline expanded sharply after new clinical guidelines preferred Technegas when available, while quarterly cash burn fell to A$0.9 million.
Ada Torres
29 Oct 2026

Market Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Artificial intelligence stocks led the week, while miners and established companies delivered a broad run of stronger profits and dividends.
Large price gaps also showed that good company news did not always produce lasting buying.
Logan Eniac
29 Aug 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

Cyclopharm’s US Surge Drives Record Half-Year Revenue of $17.5 Million

Cyclopharm Limited posted a fifth consecutive record half-year revenue of $17.5 million, propelled by a 74% jump in US Technegas® sales and a doubling of revenue-generating US sites. New US clinical guidelines naming Technegas® as the preferred ventilation imaging agent underpin a robust growth outlook despite a wider net loss.
Ada Torres
24 Aug 2026

Market Wrap - Week 31 (27 July -> 31 July) 2026

Small-cap shares produced the week’s biggest moves, led by Xenitra’s 60% surge and Carnaby Resources’ takeover jump.
Mining news dominated, but sharp falls in Lotus Resources and several funded developers showed that new capital can still unsettle investors.
Logan Eniac
1 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

US Lung Imaging Guidelines Endorse Technegas as Preferred Agent

Cyclopharm’s Technegas® has been named the preferred ventilation agent in new US lung imaging guidelines, marking the first update in 14 years and potentially accelerating adoption across American hospitals.
Ada Torres
29 July 2026

Market Wrap - Week 29 (13 July -> 17 July) 2026

Wild swings hit the ASX this week, with Janus Electric doubling, Aura sliding almost 30%, and TechGen jumping more than 22%. Big news kept landing, but many stocks still fell as early gains faded and traders locked in profits.
Logan Eniac
18 July 2026

Healthcare Wrap - Week 29 (13 July -> 17 July) 2026

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.
Logan Eniac
18 July 2026

Cyclopharm Secures Immediate 11-Site Technegas Rollout with University Hospitals Cleveland

Cyclopharm has landed a major US expansion deal with University Hospitals Cleveland, deploying Technegas® across 11 sites simultaneously and boosting its recurring revenue base in the Midwest.
Ada Torres
15 July 2026

Market Wrap - Week 27 (29 June -> 3 July) 2026

A tiny gold explorer, a battery materials stock and a biotech name led a week packed with dealmaking, drilling news and fresh funding. Resources did most of the heavy lifting, while several big gaps either held firm or gave back part of their early jump.
Logan Eniac
4 July 2026